Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
This study investigated whether volixibat could reduce the amount of fat in the liver and reduce liver injury in adults with an advanced form of non-alcoholic fatty liver disease. Volixibat did not reduce the amount of fat in the liver, nor did it have any other beneficial effect on liver injury. Participants in the study generally tolerated the side effects of volixibat and, as in previous studies, the main side effect was diarrhoea. These results show that volixibat is not an effective treatment for people with fatty liver disease.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Philip N. Newsome, Melissa Palmer, Bradley Freilich, Muhammad Y. Sheikh, Aasim Sheikh, Harry Sarles, Robert Herring, Parvez Mantry, Zeid Kayali, Tarek Hassanein, Hak-Myung Lee, Guruprasad P. Aithal, Volixibat in Adults study group Source Type: research